PROTEIN INTERACTION CORE

蛋白质相互作用核心

基本信息

项目摘要

DESCRIPTION: In a post-genomic era, systems analyses have revealed interconnected networks between gene products. Such networks predict the relationship between interacting proteins and group proteins into clusters to facilitate definition of protein function. Understanding networks of protein-protein interactions in the brain will undoubtedly lead to a better understanding of neurological diseases and identify new targets for therapeutic agents. Several large scale projects have used high throughput yeast two hybrid (Y2H) analyses to identify interacting products of open reading frames (ORES) of an organism. Functionally important protein interaction networks were defined and, for C elegans, it was shown that essential proteins often interact with one another ^^¿^^. Similar analyses are useful for discovering common mechanisms of disorders of CNS development as illustrated by a recent study that examined a protein interaction network of cerebellar ataxias by Y2H and networking analyses ^^. The power of the Y2H approach in elucidating pathogenic mechanisms of neurodegenerative disorders is remarkable. Many human neurodegenerative, developmental, and cognitive function disorders have been associated with multiple alleles. Multiple genes or genetic loci have also been implicated in complex disorders such as autism ^¿. Linkage analysis suggests that many genetic loci are associated with autism and it is conceivable that the genes associated with autism could interconnect, having effects on similar cellular pathways (13-14,19). In addition, studies of diseases associated with a single gene have also benefited from studies of protein interactions. It is estimated that -80% of disease-associated SNPs destabilize a protein's structure and thereby may alter interactions with other proteins (2,38,41). Efforts to understand how protein interactions mediate complex biological processes are maior components of the research goals of NINDS supported investigators at UAB. Core C will facilitate progress in these areas. We propose to maintain a Protein Interaction Core that offers expression of proteins in both prokaryotic and eukaryotic expression systems suitable for protein purification in-vitro and expression in-vivo, vector design and selection for in-vitro and in-vivo expression, biochemical and imaging characterization of protein interactions including FRET and split luciferase/GFP, yeast two-hybrid screening systems and generation of constructs for tandem affinity purification (TAP) and mass spectroscopy. The goal of the Core Laboratory is to accelerate identification and characterization of biologically important protein interactions without the need to establish these methodologies in individual NINDS supported laboratories. The Core Laboratory personnel will assist investigators in selection of appropriate screening systems, generate expression vector constructs for screening assays, and provide troubleshooting and technical assistance in the screening procedures. The Core Laboratory will also facilitate the exchange of reagents and more importantly, expand an information and reagent sharing resource (www.neurosciencecore.uab.edu/coreclinks.htm ) that will permit individual laboratories to share relevant experience with protein expression systems and interacting protein screening systems with other NINDS supported investigators at UAB. Finally, the core laboratory will limit redundancy in development of these methodologies and permit more efficient use of the resources provided by NINDS to investigate protein function in complex biologic systems that are the focus of study by NINDS supported investigators at UAB. Table 1 provides several examples of the interaction of the Protein Interaction Core Core C) with NINDS supported UAB investigators.
描述:在基因组后时代,系统分析揭示了基因产品之间的互连网络。这样的网络预测了相互作用的蛋白质与组蛋白之间的关系到簇中,以促进蛋白质功能的定义。了解大脑中蛋白质 - 蛋白质相互作用的网络无疑会更好地理解神经系统疾病并确定治疗剂的新靶标。 几个大型项目使用了高通量酵母两种混合(Y2H)分析来识别有机体开放阅读框(矿石)的相互作用产品。定义了功能上重要的蛋白质相互作用网络,对于秀丽隐杆线虫,结果表明,必需蛋白通常相互作用^^。^^。 类似的分析对于发现CNS发育疾病的常见机制很有用,如最近的一项研究所示,该研究检查了通过Y2H和网络分析的小脑共济失调的蛋白质相互作用网络^^。 Y2H方法在阐明神经退行性疾病的致病机制方面的功能是显着的。 许多人类神经退行性,发育和认知功能障碍与多个等位基因有关。在自闭症等复杂疾病中,也暗示了多个基因或遗传位置。链接分析表明,许多遗传局部与自闭症有关,可以想象 与自闭症相关的基因可能会互连,对相似的细胞途径产生影响(13-14,19)。此外,与单个基因相关的疾病的研究也受益于蛋白质相互作用的研究。据估计,与疾病相关的SNP中的-80%破坏了蛋白质的结构,因此可能会改变 与其他蛋白质的相互作用(2,38,41)。了解蛋白质相互作用如何介导复杂的生物学过程的努力是NINDS研究目标的Maior组成部分。 核心C将促进这些领域的进步。 我们建议维持蛋白质相互作用核心,该核心在原核和真核表达系统中提供蛋白质的表达 包括FRET和分裂荧光素酶/GFP的相互作用,酵母的两杂化筛选系统以及串联亲和纯度纯化(TAP)和质谱的结构的产生。核心实验室的目的是加速和表征生物学上重要的蛋白质相互作用,而无需 在各个ninds支持实验室中建立这些方法。核心实验室人员将协助研究人员选择适当的筛选系统,生成表达矢量构造以进行筛选测定,并在筛选程序中提供故障排除和技术帮助。 核心实验室还将促进试剂的交换,更重要的是,扩展信息和试剂共享资源(www.neurosciencecore.uab.edu/coreclinks.htm) 实验室与蛋白质表达系统共享相关经验,并与其他NINDS支持UAB的研究人员相互作用的蛋白质筛选系统。最后,核心实验室将限制这些方法开发的冗余,并允许更有效地利用NINDS提供的资源来研究复杂生物系统中的蛋白质功能,这是NINDS支持UAB研究人员的研究重点。表1提供了蛋白质相互作用核心核心与NINDS支持的UAB研究者相互作用的几个示例。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William Jarvis Britt其他文献

William Jarvis Britt的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William Jarvis Britt', 18)}}的其他基金

Tegument Envelope Protein Interactions in CMV Envelopment
CMV 包膜中的皮膜包膜蛋白相互作用
  • 批准号:
    10573700
  • 财政年份:
    2022
  • 资助金额:
    $ 16.87万
  • 项目类别:
CMV Vaccines: Reinfection and Antigenic Variation
CMV 疫苗:再感染和抗原变异
  • 批准号:
    10019411
  • 财政年份:
    2019
  • 资助金额:
    $ 16.87万
  • 项目类别:
CMV Vaccines: Reinfection and Antigenic Variation
CMV 疫苗:再感染和抗原变异
  • 批准号:
    10488568
  • 财政年份:
    2019
  • 资助金额:
    $ 16.87万
  • 项目类别:
CMV Vaccines: Reinfection and Antigenic Variation
CMV 疫苗:再感染和抗原变异
  • 批准号:
    10686167
  • 财政年份:
    2019
  • 资助金额:
    $ 16.87万
  • 项目类别:
CMV Vaccines: Reinfection and Antigenic Variation (Vision and auditory screening in infants born to women enrolled in ZIP)
CMV 疫苗:再感染和抗原变异(参加 ZIP 的妇女所生婴儿的视力和听觉筛查)
  • 批准号:
    9472616
  • 财政年份:
    2017
  • 资助金额:
    $ 16.87万
  • 项目类别:
Inflammation and Hearing Loss Following Congenital CMV Infection
先天性巨细胞病毒感染后的炎症和听力损失
  • 批准号:
    9759910
  • 财政年份:
    2017
  • 资助金额:
    $ 16.87万
  • 项目类别:
Inflammation and Hearing Loss Following Congenital CMV Infection
先天性巨细胞病毒感染后的炎症和听力损失
  • 批准号:
    10238050
  • 财政年份:
    2017
  • 资助金额:
    $ 16.87万
  • 项目类别:
HCMV miRNA Regulation of Secretion and Formation of the Viral Assembly Compartment
HCMV miRNA 对病毒装配室的分泌和形成的调节
  • 批准号:
    9883699
  • 财政年份:
    2016
  • 资助金额:
    $ 16.87万
  • 项目类别:
HCMV miRNA Regulation of Secretion and Formation of the Viral Assembly Compartment
HCMV miRNA 对病毒装配室的分泌和形成的调节
  • 批准号:
    9250666
  • 财政年份:
    2016
  • 资助金额:
    $ 16.87万
  • 项目类别:
Congenital CMV and CNS Infection Mechanisms of Protective Immunity
先天性巨细胞病毒和中枢神经系统感染的保护性免疫机制
  • 批准号:
    8450754
  • 财政年份:
    2011
  • 资助金额:
    $ 16.87万
  • 项目类别:

相似国自然基金

基于sIgA的V(D)J结构多样性探索腺病毒载体鼻喷新冠奥密克戎疫苗诱导的呼吸道粘膜免疫原性特征
  • 批准号:
    82302607
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
新型腺病毒载体Ad49L介导的高水平干扰素α抑制疫苗体液免疫的机制
  • 批准号:
    82302001
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
新型腺病毒载体疫苗长效免疫机制
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    53 万元
  • 项目类别:
    面上项目
新型腺病毒载体疫苗长效免疫机制
  • 批准号:
    82271868
  • 批准年份:
    2022
  • 资助金额:
    53.00 万元
  • 项目类别:
    面上项目
基于肠道腺病毒载体平台COVID-19粘膜疫苗的设计与筛选
  • 批准号:
    82161138001
  • 批准年份:
    2021
  • 资助金额:
    150 万元
  • 项目类别:
    国际(地区)合作与交流项目

相似海外基金

Advancing Systematic Delivery of Oncolytic Adenovirus for Pancreatic Cancer
推进溶瘤腺病毒治疗胰腺癌的系统递送
  • 批准号:
    10734709
  • 财政年份:
    2023
  • 资助金额:
    $ 16.87万
  • 项目类别:
Lentivirus Construct Core
慢病毒构建核心
  • 批准号:
    10630391
  • 财政年份:
    2023
  • 资助金额:
    $ 16.87万
  • 项目类别:
A novel therapeutic approach for Alzheimer Disease (AD)
阿尔茨海默病(AD)的新治疗方法
  • 批准号:
    10740016
  • 财政年份:
    2023
  • 资助金额:
    $ 16.87万
  • 项目类别:
Pulmonary endothelium targeted adenoviral gene therapy for the correction of mucopolysaccharidosis type I
肺内皮靶向腺病毒基因治疗纠正 I 型粘多糖贮积症
  • 批准号:
    10678053
  • 财政年份:
    2023
  • 资助金额:
    $ 16.87万
  • 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
  • 批准号:
    10591804
  • 财政年份:
    2023
  • 资助金额:
    $ 16.87万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了